Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Nadler

Interventional Pain Medicine Overland Park, KS Medical Doctor

NPI 1063414225 CMS profile 2268

8101 W 135Th St, Suite 200, Overland Park, KS 66223

Open in the dashboard

General payments

$5,140

128 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Nadler of Overland Park, KS is reported in the CMS Open Payments database as having received $5,140 across 128 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $646 17
2024 General $372 7
2023 General $350 6
2022 General $24 1
2021 General $180 11
2020 General $307 7
2019 General $3,261 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Nadler
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Matthew Nadler were reported at $646. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Matthew Nadler Interventional Pain Medicine median Middle half National median
2019 $3,261 $684 $216–$2,079 $163
2020 $307 $382 $122–$1,109 $114
2021 $180 $552 $167–$1,554 $132
2022 $24 $605 $187–$1,924 $149
2023 $350 $671 $195–$1,915 $160
2024 $372 $684 $206–$1,837 $164
2025 $646 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $906 5 payments
  2. Boston Scientific Corporation $828 14 payments
  3. Saluda Medical Americas, Inc. $494 10 payments
  4. Amgen Inc. $471 11 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $319 20 payments
  6. Daiichi Sankyo Inc. $237 8 payments
  7. Bioness Inc $201 1 payment
  8. Medtronic USA, Inc. $200 3 payments
  9. TerSera Therapeutics LLC $181 10 payments
  10. SPR Therapeutics, Inc $157 4 payments
  11. Other $1,147 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,157 125 payments
  2. Travel and Lodging $782 2 payments
  3. Entertainment $201 1 payment
Products named General payments · program years 2019–2025
  1. AIMOVIG $527 15 payments
  2. IVS - MULTIGEN 2RF $512 2 payments
  3. Evoke $494 10 payments
  4. IVS - VERTEBRAL AUGMENTATION PRODUCTS $393 3 payments
  5. WaveWriter Alpha Prime 16 $293 3 payments
  6. Morphabond ER $237 8 payments
  7. RELISTOR $209 7 payments
  8. Stimrouter for Pain $201 1 payment
  9. PRIALT $181 10 payments
  10. SPRINT PNS System $157 4 payments
  11. Other $1,527 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

4,590

Median for Pain Management: 951

Drug cost

$90,694

Median for Pain Management: $26,034

Branded share of claims

19.9%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 78 $19,520
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 532 $13,744
Gabapentin Generic 821 $9,419
Tizanidine Hcl Generic 581 $7,728
Baclofen Generic 494 $7,004
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 201 $5,078
Lidocaine Generic 40 $3,564
Tramadol Hcl Generic 310 $3,302
Pregabalin Generic 165 $2,939
Fentanyl Generic 30 $2,795

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$61,661

Medicare's payments for the services billed

Medicare patients

151

Average age 72

Services billed

982

88 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 36%
Depression 34%
COPD 31%
Ischemic heart disease 29%
Chronic kidney disease 26%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

128 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record